Infinity Announces the Date of Its First Quarter Financial Results Conference Call and Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Monday, May 11, 2020 at 4:30 p.m. ET to review its first quarter 2020 financial results and provide an update on the company.

A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com. To participate in the conference call, please dial [phone] (domestic) and [phone] (international) five minutes prior to start time. The conference ID number is 1978798. An archived version of the webcast will be available on Infinity's website for 30 days.

About Infinity and IPI-549

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, controlled combination study of IPI-549 combined with Opdivo (nivolumab) in I/O naïve urothelial cancer. MARIO-3 is the first IPI-549 combination study in front-line advanced cancer patients and is evaluating IPI-549 in combination with Tecentriq and Abraxane in front-line TNBC and in combination with Tecentriq and Avastin in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of IPI-549 plus AB928 (dual adenosine receptor antagonist) plus Doxil in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating IPI-549 as a monotherapy and in combination with Opdivo in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating IPI-549 in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo is a registered trademark of Bristol-Myers Squibb.
Tecentriq and Avastin are registered trademarks of Roche.
Abraxane is a registered trademark of Celgene.
Doxil is a registered trademark of Janssen Products.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200504005140/en/